secwatch / observer
8-K filed April 17, 2023, 7:59 PM ET ticker REGN CIK 0000872589
leadership confidence high sentiment neutral materiality 0.65

Regeneron Chair P. Roy Vagelos not to stand for re-election; Schleifer and Yancopoulos named Co-Chairs

REGENERON PHARMACEUTICALS, INC.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

P. Roy Vagelos

Chair of the Board
REGN · REGENERON PHARMACEUTICALS, INC.
Effective
2023-06-09
Successor
Leonard S. Schleifer and George D. Yancopoulos
Filed
April 17, 2023, 7:59 PM ET
Dr. Vagelos will continue to serve as Chair of the Board for the remainder of his term until the conclusion of the 2023 Annual Meeting.
Appointed

George D. Yancopoulos

Co-Chair of the Board
REGN · REGENERON PHARMACEUTICALS, INC.
Effective
2023-06-09
Filed
April 17, 2023, 7:59 PM ET
the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board
Appointed

Leonard S. Schleifer

Co-Chair of the Board
REGN · REGENERON PHARMACEUTICALS, INC.
Effective
2023-06-09
Filed
April 17, 2023, 7:59 PM ET
the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board
Appointed

Christine A. Poon

Lead Independent Director
REGN · REGENERON PHARMACEUTICALS, INC.
Effective
2023-06-09
Filed
April 17, 2023, 7:59 PM ET
and to designate Christine A. Poon as the Lead Independent Director of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

P. Roy Vagelos departed as Chair of the Board at REGENERON PHARMACEUTICALS, INC..

Action
not stand for re-election
Role
Chair of the Board
Exact text from the filing
Dr. Vagelos will continue to serve as Chair of the Board for the remainder of his term until the conclusion of the 2023 Annual Meeting.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

George D. Yancopoulos was elected as Co-Chair of the Board at REGENERON PHARMACEUTICALS, INC..

Action
elected
Role
Co-Chair of the Board
Exact text from the filing
the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Leonard S. Schleifer was elected as Co-Chair of the Board at REGENERON PHARMACEUTICALS, INC..

Action
elected
Role
Co-Chair of the Board
Exact text from the filing
the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Christine A. Poon was appointed as Lead Independent Director at REGENERON PHARMACEUTICALS, INC..

Action
designated
Role
Lead Independent Director
Exact text from the filing
and to designate Christine A. Poon as the Lead Independent Director of the Board
View on SEC.gov

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR
accession 0001104659-23-045897
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.